{"id":"amlodipine-olmesartan","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Peripheral edema"},{"rate":"5-8","effect":"Headache"},{"rate":"3-5","effect":"Dizziness"},{"rate":"2-4","effect":"Fatigue"},{"rate":"1-3","effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL1200692","moleculeType":"Small molecule","molecularWeight":"558.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation. Olmesartan is an angiotensin II receptor blocker (ARB) that antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction and aldosterone release. Together, these complementary mechanisms provide additive antihypertensive effects.","oneSentence":"Amlodipine relaxes blood vessels by blocking calcium channels, while olmesartan blocks angiotensin II receptors to reduce vasoconstriction and lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:40.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT05660135","phase":"","title":"Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":"Hypertension, Dyslipidemias","enrollment":4000},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT04120753","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-08-26","conditions":"Hypertension, Dyslipidemias","enrollment":106},{"nctId":"NCT05917275","phase":"PHASE4","title":"Multi-Omics to Predict the Blood Pressure Response to Antihypertensives","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-04-04","conditions":"Primary Hypertension","enrollment":96},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT05189015","phase":"PHASE4","title":"Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2021-01-01","conditions":"Angiotensin/Renin/Aldosterone Hypertension, Hypertension, Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT03009487","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-01","conditions":"Hypertension, Hyperlipidemias","enrollment":265},{"nctId":"NCT01200407","phase":"","title":"Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-06-09","conditions":"Hypertension","enrollment":615},{"nctId":"NCT03015311","phase":"NA","title":"Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2017-01-15","conditions":"Primary Hypertension","enrollment":8000},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT01870739","phase":"PHASE2","title":"A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Hypertension","enrollment":115},{"nctId":"NCT00523744","phase":"PHASE3","title":"Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-07","conditions":"Hypertension","enrollment":257},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT04161001","phase":"PHASE3","title":"Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-11-20","conditions":"Hypertension, Dyslipidemia","enrollment":237},{"nctId":"NCT02449811","phase":"","title":"RAS Peptide Profiles in Patients With Arterial Hypertension","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Essential Hypertension","enrollment":107},{"nctId":"NCT00902538","phase":"PHASE3","title":"Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-04","conditions":"Essential Hypertension","enrollment":2204},{"nctId":"NCT00923091","phase":"PHASE3","title":"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-06","conditions":"Essential Hypertension","enrollment":2689},{"nctId":"NCT00649389","phase":"PHASE3","title":"Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-05","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT00791258","phase":"PHASE4","title":"A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Hypertension","enrollment":999},{"nctId":"NCT01838850","phase":"PHASE3","title":"Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy","status":"COMPLETED","sponsor":"Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":344},{"nctId":"NCT00220220","phase":"PHASE3","title":"Amlodipine as add-on to Olmesartan in Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2005-04","conditions":"Essential Hypertension","enrollment":429},{"nctId":"NCT00891267","phase":"PHASE3","title":"Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2008-10","conditions":"Metabolic Syndrome, Hypertension","enrollment":60},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT00185133","phase":"PHASE3","title":"Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-05","conditions":"Hypertension","enrollment":1900},{"nctId":"NCT00220233","phase":"PHASE3","title":"Olmesartan as an add-on to Amlodipine in Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2005-04","conditions":"Essential Hypertension","enrollment":632},{"nctId":"NCT03753477","phase":"PHASE1","title":"Clinical Trial to Investigate the Efficacy and Safety of DWJ1351","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-12-22","conditions":"Healthy","enrollment":64},{"nctId":"NCT01083017","phase":"","title":"Resistant Arterial Hypertension Cohort Study","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2011-04","conditions":"Hypertension, Essential Hypertension, Resistant Hypertension","enrollment":74},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT03024476","phase":"PHASE2","title":"Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2016-09-01","conditions":"Ischemic Stroke, Hypertension","enrollment":67},{"nctId":"NCT02377661","phase":"PHASE4","title":"Lowering Blood Pressure in Primary Care in Vienna","status":"COMPLETED","sponsor":"Wilhelminenspital Vienna","startDate":"2015-03","conditions":"Hypertension","enrollment":229},{"nctId":"NCT01611077","phase":"PHASE4","title":"Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2012-01","conditions":"Hypertension","enrollment":88},{"nctId":"NCT02996916","phase":"PHASE4","title":"Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-12","conditions":"Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension","enrollment":100},{"nctId":"NCT02962258","phase":"PHASE1","title":"BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-05","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT02962336","phase":"PHASE1","title":"Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-05","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT01613209","phase":"PHASE3","title":"Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2011-12","conditions":"Hypertension","enrollment":83},{"nctId":"NCT02665832","phase":"PHASE1","title":"Study of DWJ1351 in Healthy Male Volunteers","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2016-01","conditions":"Healthy","enrollment":58},{"nctId":"NCT01089452","phase":"PHASE4","title":"Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study","status":"WITHDRAWN","sponsor":"Monash University","startDate":"","conditions":"Hypertension","enrollment":""},{"nctId":"NCT02089399","phase":"PHASE1","title":"Pharmacokinetics and Drug Interaction Study Between Amlodipine,Olmesartan and Rosuvastatin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2014-05","conditions":"Healthy","enrollment":32},{"nctId":"NCT02128386","phase":"","title":"Medication Adherence and \"True\" Resistance in Patients With Resistant Hypertension","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2014-02","conditions":"Hypertensive Disease, Hypertension, Resistant to Conventional Therapy","enrollment":50},{"nctId":"NCT02058472","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2013-12","conditions":"Healthy Adult Volunteers","enrollment":30},{"nctId":"NCT01113047","phase":"PHASE3","title":"Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-05","conditions":"Essential Hypertension","enrollment":347},{"nctId":"NCT00454662","phase":"PHASE4","title":"Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)","status":"COMPLETED","sponsor":"COLM Study Research Organization","startDate":"2007-04","conditions":"Hypertension, Cardiovascular Disease, Diabetes","enrollment":5141},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00834600","phase":"NA","title":"Renin Profiling in Selection of Initial Antihypertensive Drug","status":"COMPLETED","sponsor":"The Louis & Rachel Rudin Foundation","startDate":"2005-12","conditions":"Hypertension","enrollment":185},{"nctId":"NCT00185120","phase":"PHASE4","title":"Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-09","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01180205","phase":"PHASE4","title":"Telmisartan, Amlodipine and Flow Mediated Dilation","status":"UNKNOWN","sponsor":"Johannes Gutenberg University Mainz","startDate":"2010-08","conditions":"Hypertension","enrollment":576},{"nctId":"NCT01271374","phase":"PHASE4","title":"Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome","status":"UNKNOWN","sponsor":"InVasc Therapeutics, Inc.","startDate":"2010-04","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00311155","phase":"PHASE4","title":"Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2006-03","conditions":"Essential Hypertension","enrollment":694},{"nctId":"NCT00134160","phase":"PHASE4","title":"OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study","status":"COMPLETED","sponsor":"OSCAR Study","startDate":"2005-08","conditions":"Hypertension, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT00654745","phase":"PHASE4","title":"18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-05","conditions":"Type 2 Diabetes, Hypertension","enrollment":207},{"nctId":"NCT00527514","phase":"PHASE3","title":"Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-09","conditions":"Hypertension","enrollment":185},{"nctId":"NCT00890591","phase":"PHASE4","title":"Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-08","conditions":"Essential Hypertension","enrollment":144},{"nctId":"NCT00772499","phase":"PHASE4","title":"Vascular Improvement With Olmesartan Medoxomil Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-11","conditions":"Hypertension","enrollment":100},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[{"count":30,"reaction":"DIARRHOEA"},{"count":22,"reaction":"FATIGUE"},{"count":21,"reaction":"NAUSEA"},{"count":20,"reaction":"PAIN"},{"count":19,"reaction":"DRUG INEFFECTIVE"},{"count":18,"reaction":"DIZZINESS"},{"count":16,"reaction":"DEATH"},{"count":16,"reaction":"HEADACHE"},{"count":13,"reaction":"ANXIETY"},{"count":13,"reaction":"CONFUSIONAL STATE"}],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amlodipine/Olmesartan","genericName":"Amlodipine/Olmesartan","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine relaxes blood vessels by blocking calcium channels, while olmesartan blocks angiotensin II receptors to reduce vasoconstriction and lower blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}